SAVI — STING-Associated Vasculopathy with Infancy Onset, a type I interferonopathy caused by heterozygous gain-of-function mutations in the TMEM173 gene encoding STING (Stimulator of Interferon Genes), a transmembrane adapter protein in the endoplasmic reticulum that senses cytosolic double-stranded DNA via the cGAS-STING pathway and activates IRF3 and NF-κB to induce type I interferon (IFN-α/β) production and pro-inflammatory cytokine secretion, with pathogenic SAVI variants — N154S, V155M, G166E, C206Y, R281Q, R284G, S102P, and others affecting the STING dimerization interface — constitutively activating STING signaling independently of its ligand, driving tonically elevated type I interferon production and downstream ISG (interferon-stimulated gene) expression that causes a severe, neonatal-onset systemic vasculopathy; SAVI typically presents in the first weeks to months of life with low birth weight, failure to thrive, recurrent fever, and markedly elevated inflammatory markers — ESR, CRP, ferritin — followed by the development of the pathognomonic skin manifestations — violaceous, telangiectatic, and eventually ulcerating lesions at acral sites (fingertips, toes, earlobes, nose, cheeks) representing a cutaneous small vessel vasculitis with intravascular thrombosis and ischemia, culminating in digital necrosis, autoamputation of fingertips and toes, and disfiguring facial scarring — and interstitial lung disease (ILD), the most life-threatening SAVI manifestation, driven by type I interferon-mediated alveolar inflammation producing a ground-glass and fibrotic pattern on high-resolution CT (HRCT) of the chest that progressively reduces pulmonary function and causes pulmonary hypertension, respiratory failure, and early death without effective therapy; laboratory hallmarks include massively elevated interferon-alpha serum levels measurable by SIMOA (single molecule array) assay, markedly elevated ISG scores (the Interferon Score — a gene expression signature in peripheral blood measuring transcript levels of ISG15, IFIT1, IFIT2, IFIT3, RSAD2, and SIGLEC1 that quantifies the type I interferon response and serves as a SAVI disease activity biomarker), elevated anti-MDA5 antibodies in a subset, and elevated CXCL10; SAVI is treated with JAK inhibitors — ruxolitinib (JAK1/2 inhibitor) and baricitinib (JAK1/2 inhibitor) — which suppress type I interferon downstream signaling through JAK-STAT pathway inhibition, reducing ISG scores, improving skin vasculopathy, and stabilizing or improving pulmonary function; the disease shares phenotypic overlap with Aicardi-Goutières syndrome and other type I interferonopathies, and TMEM173 gain-of-function mutations represent one of the most directly therapeutically targetable interferonopathy mechanisms currently identified.
SAVI technology platforms — encompassing the neonatology and pediatric rheumatology platforms where the neonatal-onset inflammatory vasculopathy and ILD combination raises the type I interferonopathy suspicion and TMEM173 genetic testing is initiated, the genetic testing platforms where TMEM173 gain-of-function variant analysis confirms the SAVI diagnosis and distinguishes pathogenic constitutional mutations from somatic mosaic variants and variants of uncertain significance, the immunology laboratory platforms measuring the type I interferon signature — including SIMOA IFN-α quantification and ISG score panels — that serve as SAVI diagnostic biomarkers and JAK inhibitor treatment response markers, the pulmonology platforms managing the interstitial lung disease including HRCT surveillance, pulmonary function testing, six-minute walk testing, and oxygen saturation monitoring, the dermatology platforms managing the cutaneous vasculopathy including digital ischemia wound care, ulcer documentation, and telangiectatic lesion progression tracking, the JAK inhibitor management platforms coordinating ruxolitinib or baricitinib prescribing, dose titration, laboratory safety monitoring (CBC, LFTs, lipids, renal function), infection prophylaxis (PCP prophylaxis with trimethoprim-sulfamethoxazole, varicella vaccination precautions, herpes zoster risk management), and ISG score response documentation, the vascular surgery and wound care platforms managing digital ischemia and autoamputation wound care, and the multidisciplinary SAVI coordination platforms aligning neonatology, pediatric rheumatology, pulmonology, dermatology, and immunogenetics — must maintain the availability and performance standards required by the type I interferon signature monitoring precision, ILD progression surveillance urgency, JAK inhibitor management complexity, and digital vasculopathy wound care intensity that define modern SAVI management. This guide explains why SAVI tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the TMEM173 genetic confirmation, ISG score tracking, HRCT pulmonary surveillance, JAK inhibitor response monitoring, and cutaneous vasculopathy wound documentation that define modern SAVI care.
Why SAVI Tech Platforms Require Specialized Monitoring Attention
SAVI management is defined by several uniquely complex type I interferonopathy management challenges: the neonatal-onset urgency — SAVI presents in the first weeks of life with a systemic inflammatory phenotype that rapidly causes irreversible pulmonary fibrosis and digital ischemia if not diagnosed and treated promptly; the ISG score monitoring precision — the Interferon Score, a quantitative peripheral blood ISG transcript measurement, is the principal SAVI disease activity biomarker and the primary metric for JAK inhibitor dose adequacy, requiring a specialized immunology platform that is not standard in most laboratory information systems; the ILD progression surveillance — HRCT characterization of ground-glass opacification and fibrosis extent, pulmonary function testing trajectories, and oxygen saturation monitoring define the life-threatening dimension of SAVI and determine JAK inhibitor dosing escalation; and the JAK inhibitor safety monitoring — ruxolitinib and baricitinib cause dose-dependent cytopenias, elevated lipids, liver function perturbations, and increased herpes zoster and opportunistic infection risk requiring vigilant laboratory surveillance.
TMEM173 genetic testing platforms confirm the gain-of-function interferonopathy. The identification of heterozygous gain-of-function TMEM173 variants by NGS interferonopathy panel, whole exome sequencing, or whole genome sequencing establishes the SAVI diagnosis, guides type I interferonopathy specialist referral, and identifies the JAK inhibitor targets for treatment. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
ISG score platforms are the SAVI disease activity and treatment response biomarker. Serial Interferon Scores — quantifying peripheral blood transcript levels of ISG15, IFIT1, IFIT2, IFIT3, RSAD2, and SIGLEC1 by NanoString, Fluidigm, or RT-PCR — are the primary metric confirming SAVI diagnosis and monitoring JAK inhibitor adequacy. Monitor ISG score platforms at 1-minute intervals during laboratory hours.
HRCT and pulmonary function platforms track the life-threatening ILD. Serial HRCT scoring of ground-glass, consolidation, and fibrosis extent, plus pulmonary function test trajectories (FVC, DLCO), define the disease's most fatal complication and determine treatment escalation urgency. Monitor pulmonary imaging and function platforms at 1-minute intervals during operational hours.
JAK inhibitor management platforms coordinate ruxolitinib and baricitinib therapy. Dose titration, CBC monitoring for cytopenias, LFT and lipid surveillance, PCP prophylaxis prescribing, and ISG score response documentation require reliable platform availability throughout the treatment course. Monitor JAK inhibitor management platforms at 1-minute intervals during clinical hours.
Cutaneous vasculopathy and wound care platforms document digital ischemia progression. Digital telangiectasia, ulceration, and autoamputation wound care documentation platforms must be available to dermatology, wound care nursing, and vascular surgery to coordinate the management of SAVI's most visible and disfiguring complication. Monitor wound care platforms at 1-minute intervals during clinical hours.
What to Monitor on a SAVI Tech Platform
Genetic Testing — TMEM173 Gain-of-Function Variant Analysis
Monitor genetic testing referral records (clinical suspicion documentation — neonatal or early infantile onset vasculopathy, ILD, elevated type I interferon signature, failure to thrive, acral ischemic lesions, family history of similar presentation, ethnicity-agnostic occurrence), TMEM173 molecular testing records (NGS interferonopathy gene panel including TMEM173 sequencing and structural variant analysis, whole exome sequencing, or whole genome sequencing — identification of heterozygous gain-of-function variants N154S, V155M, G166E, C206Y, R281Q, R284G, S102P and other activating variants; somatic mosaic variant detection for patients with atypical presentation), functional validation records (STING phosphorylation assay, IRF3 activation assay, and ISG reporter assay confirmatory testing for novel TMEM173 variants of uncertain significance), genotype-phenotype correlation records (V155M and N154S variants associated with more severe ILD; mapping to dimerization interface versus other structural domains), and genetic counseling records (de novo dominant mutation frequency in SAVI — majority are de novo, but affected parents and germline mosaicism documented) at 1-minute intervals during laboratory hours. Alert immediately — TMEM173 panel result delays in a 6-week-old presenting with failure to thrive, bilateral ground-glass ILD on chest CT, and erythematous telangiectatic patches on the fingertips and earlobes delay the interferonopathy diagnosis that prompts JAK inhibitor initiation before irreversible pulmonary fibrosis progresses.
Interferon Signature — ISG Score Monitoring
Monitor ISG score assay records (Interferon Score by NanoString nCounter or RT-PCR quantification of ISG15, IFIT1, IFIT2, IFIT3, RSAD2, and SIGLEC1 transcript levels normalized to housekeeping genes — ISG scores greater than 2 standard deviations above healthy control mean confirming type I interferonopathy; ISG score magnitude correlating with disease activity), serial ISG score trajectory records (at diagnosis, 1 month after JAK inhibitor initiation, 3 months, and quarterly thereafter — the primary metric for JAK inhibitor dose adequacy and persistent type I interferon suppression), SIMOA IFN-α quantification records (serum IFN-α levels by ultrasensitive single molecule array assay — extremely elevated in active SAVI, declining with effective JAK inhibition), CXCL10 records (CXCL10/IP-10 as a complementary interferon-inducible chemokine biomarker — more accessible than ISG scoring in standard laboratory settings), and ISG score normalization failure records (persistently elevated ISG scores on JAK inhibitor treatment triggering dose escalation discussion) at 1-minute intervals during laboratory hours. Alert immediately — ISG score platform failures when a 14-month-old SAVI patient on ruxolitinib has an ISG score measurement pending that will determine whether the current dose is suppressing the interferon signature sufficiently or whether the dose must be escalated before the next HRCT shows progression of ground-glass ILD.
Pulmonology — Interstitial Lung Disease Monitoring
Monitor HRCT records (high-resolution CT chest scoring — ground-glass opacification extent and distribution, consolidation areas, interlobular septal thickening, honeycombing, traction bronchiectasis, subpleural distribution; modified Bhalla or Reiff score documenting ILD severity; interval comparison for progression or stabilization under JAK inhibition), pulmonary function test records (FVC, FEV1, FEV1/FVC, TLC, DLCO — the DLCO trajectory particularly important for SAVI ILD quantifying interstitial inflammation and fibrosis; FVC below 70% predicted triggering enhanced monitoring; FVC below 50% prompting NIV assessment), six-minute walk test records (exercise capacity documentation — 6MWT distance and oximetry desaturation during exertion; important for disease severity staging and JAK inhibitor response assessment), resting and exertional oxygen saturation records (baseline SpO2 and exercise-induced desaturation — supplemental oxygen requirement documentation), pulmonary hypertension screening records (echocardiography for right ventricular pressure estimation, right heart catheterization if tricuspid regurgitation jet velocity exceeds 3.4 m/s), and respiratory support records (high-flow nasal oxygen, BiPAP, and mechanical ventilation in acute respiratory deterioration) at 1-minute intervals during clinical and radiology operational hours. Alert immediately — HRCT scheduling platform failures for a 3-year-old SAVI patient on baricitinib whose ISG score has only partially normalized — when the 6-month pulmonary surveillance CT must document whether the ground-glass extent has stabilized, progressed, or improved under JAK inhibition — delay the imaging data that drives baricitinib dose escalation decisions.
JAK Inhibitor Therapy Management
Monitor ruxolitinib and baricitinib prescribing records (dose in mg/kg/day for pediatric patients, dose escalation schedule, missed dose documentation, dose hold records for adverse events), CBC monitoring records (weekly during dose escalation, monthly at stable dose — neutropenia grade 1-2 requiring dose reduction; thrombocytopenia monitoring; anemia surveillance), lipid panel records (baseline and every 3–6 months — baricitinib and ruxolitinib associated with LDL and total cholesterol elevation), LFT records (AST, ALT, alkaline phosphatase at baseline and quarterly — mild transaminase elevation common; ALT greater than 3x ULN triggering dose hold), creatinine and renal function records (baseline and quarterly — especially for baricitinib, which undergoes renal elimination), PCP prophylaxis records (trimethoprim-sulfamethoxazole prescribing and adherence documentation — mandatory during JAK inhibitor therapy), herpes zoster and varicella risk management records (VZV serostatus at baseline; varicella vaccination status and timing relative to JAK inhibitor initiation; zoster prophylaxis with acyclovir in VZV-seropositive patients), and JAK inhibitor infection surveillance records (bacterial, viral, fungal, and opportunistic infection documentation during immunosuppressive therapy) at 1-minute intervals during clinical hours. Alert immediately — CBC monitoring platform failures in a 2-year-old SAVI patient on ruxolitinib dose escalation when the weekly CBC check for treatment-emergent neutropenia cannot be recorded leave the dose escalation safety monitoring without the laboratory data required to confirm neutrophil count safety before the next dose increase.
Cutaneous Vasculopathy and Wound Care
Monitor digital vasculopathy documentation records (telangiectatic macule and papule mapping — fingertips, toes, earlobes, nose, malar cheeks; lesion size, color, and photographic documentation at standardized intervals; ulceration onset and expansion; ischemic digit assessment), wound care records (ulcer dimensions — length, width, depth; wound base characteristics; dressing type and frequency; pain management; wound healing trajectory under JAK inhibition), digital ischemia intervention records (prostacyclin infusion — iloprost — for severe digital vasospasm and ischemia; digital sympathectomy; vascular surgery consultation; amputation wound care for autoamputation sites), cold-triggered vasospasm documentation records (Raynaud-like phenomenon assessment — cold exposure triggers, vasospasm frequency and duration, finger rewarming time), and acral scarring and autoamputation records (final digit length documentation, residual function assessment, prosthetic planning) at 1-minute intervals during clinical hours. Alert on sustained failures — cutaneous vasculopathy platform failures delay the wound care team's documentation of ischemic ulcer expansion in a SAVI patient, interrupting the weekly wound measurement that tracks whether ruxolitinib is arresting digital ischemia or whether iloprost infusion is indicated.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. SAVI management coordinates across neonatology (neonatal-onset presentation), pediatric rheumatology and interferonopathy specialties (TMEM173 diagnosis, JAK inhibitor initiation), clinical immunology (ISG score monitoring, SIMOA IFN-α quantification), pulmonology (ILD surveillance), dermatology (cutaneous vasculopathy, wound care), vascular surgery (digital ischemia interventions), genetics (TMEM173 variant confirmation, genetic counseling), pharmacy (ruxolitinib/baricitinib dispensing, PCP prophylaxis), infectious disease (opportunistic infection surveillance), and international interferonopathy research coordination — authentication failures block every team member required to execute the interferon signature monitoring, pulmonary surveillance, and JAK inhibitor safety management that define SAVI care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, ISG score laboratory portals, HRCT imaging systems, pulmonary function platforms, JAK inhibitor management portals, wound care documentation systems, and interferonopathy registry platforms. Certificate errors disrupt ISG score result transmission (most critically, since JAK inhibitor dose decisions depend on this), HRCT scheduling workflows, and biologic therapy management systems.
HIPAA and Rare Type I Interferonopathy Patient Privacy Considerations
SAVI technology platforms handle highly sensitive PHI for a patient population that is globally rare — with fewer than 200 families confirmed in the published literature — predominantly presenting in infancy, and frequently subject to de novo mutations that create isolated cases without a family history that might otherwise alert the clinical team. Records include TMEM173 molecular genetic variant testing (de novo dominant gain-of-function mutation with implications for family planning and sibling risk assessment), ISG score measurements (a specialized laboratory assay not in standard LIS panels, performed at reference laboratories), neonatal HRCT chest imaging, digital ischemia wound photography, and JAK inhibitor prescribing in infants and toddlers — a setting where medication error risks are highest and pharmacy platform availability is most critical.
The heritable nature of TMEM173 gain-of-function variants creates genetic information privacy obligations under GINA and HIPAA Privacy Rule requirements. For pulmonary function monitoring platforms documenting the ILD progression that is the primary SAVI mortality driver — where platform unavailability delays the DLCO measurement that triggers JAK inhibitor escalation before irreversible fibrosis accrues — availability monitoring provides documentation relevant to HIPAA Security Rule compliance and the urgent clinical safety obligations of neonatal-onset ILD management.
Alerting Strategy for SAVI Tech Platforms
Immediate clinical-hours alerting for JAK inhibitor management platforms: CBC monitoring for cytopenias during dose escalation, LFT surveillance, lipid monitoring, PCP prophylaxis documentation, and ISG score response documentation. Weekly CBC checks during dose escalation are safety-critical.
Immediate laboratory-hours alerting for ISG score and interferon signature platforms: ISG score, SIMOA IFN-α quantification, and CXCL10 measurements. These are the disease activity biomarkers that drive JAK inhibitor dose decisions.
Immediate radiology-hours alerting for HRCT and pulmonary imaging: Chest CT scheduling, ground-glass scoring, and TLC/DLCO pulmonary function testing. ILD progression is the primary SAVI mortality driver.
Immediate laboratory-hours alerting for genetic testing platforms: TMEM173 interferonopathy panel and whole exome sequencing. Neonatal-onset ILD in an infant requires urgent diagnosis — platform failures extend the treatment-free interval during irreversible disease progression.
Immediate clinical-hours alerting for cutaneous vasculopathy and wound care platforms: Digital ischemia wound documentation and intervention records.
Sustained-failure alert (10–15 minutes): Interferonopathy registry, genetic counseling coordination, and vascular surgery platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms SAVI platform availability from the geographies where type I interferonopathy centers of excellence, TMEM173 molecular genetic testing programs, and pediatric JAK inhibitor specialty pharmacy networks concentrate — including specialized centers in France, Germany, the United Kingdom, the United States, and the Middle East.
Status Page for SAVI Care Team Communication
A real-time status page gives neonatologists and pediatric rheumatologists managing neonatal-onset interferonopathy, clinical immunologists monitoring ISG scores and IFN-α levels, pulmonologists tracking ILD progression on HRCT, dermatologists documenting digital vasculopathy, pharmacists managing ruxolitinib and baricitinib dispensing and PCP prophylaxis, geneticists confirming TMEM173 variants, wound care specialists tracking digital ischemia, and interferonopathy registry coordinators immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in JAK inhibitor dose escalation protocols (so that clinicians know when CBC monitoring platform availability is reduced during weekly dose escalation checks), ISG score laboratory emergency procedures, and TMEM173 laboratory emergency procedures.
Vigilmon Setup for SAVI Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ISG score (NanoString / RT-PCR panel) | 1 min | Slack + PagerDuty (lab hours) | | SIMOA IFN-α quantification | 1 min | Slack + PagerDuty (lab hours) | | CXCL10 / IP-10 (interferon-inducible chemokine) | 1 min | Slack + PagerDuty (lab hours) | | TMEM173 interferonopathy NGS panel / WES | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and de novo variant confirmation | 1 min | Slack + PagerDuty (lab hours) | | HRCT chest (ground-glass, fibrosis scoring) | 1 min | Slack + PagerDuty (radiology hours) | | Pulmonary function (FVC, DLCO, TLC) | 1 min | Slack + PagerDuty (clinical hours) | | Six-minute walk test and SpO2 monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Pulmonary hypertension echocardiography | 1 min | Slack + PagerDuty (radiology hours) | | Ruxolitinib / baricitinib prescribing and dose escalation | 1 min | Slack + PagerDuty (clinical hours) | | Weekly CBC (cytopenias during dose escalation) | 1 min | Slack + PagerDuty (lab hours) | | LFT and lipid monitoring (JAK inhibitor safety) | 1 min | Slack + PagerDuty (lab hours) | | PCP prophylaxis (TMP-SMX prescribing and adherence) | 1 min | Slack + PagerDuty (clinical hours) | | Digital vasculopathy wound documentation | 1 min | Slack + PagerDuty (clinical hours) | | Iloprost / vascular intervention records | 2 min | Slack (clinical hours) | | Interferonopathy registry and clinical trial access | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ISG score platforms with immediate laboratory-hours alerting — the SAVI disease activity biomarker and JAK inhibitor response metric
- Add SIMOA IFN-α quantification with immediate laboratory-hours alerting
- Configure CXCL10/IP-10 monitoring with immediate laboratory-hours alerting
- Add TMEM173 interferonopathy panel platforms with immediate laboratory-hours alerting
- Configure genetic counseling and variant confirmation platforms with immediate laboratory-hours alerting
- Add HRCT chest imaging with immediate radiology-hours alerting
- Configure pulmonary function testing (FVC, DLCO, TLC) with immediate clinical-hours alerting
- Add six-minute walk testing and SpO2 monitoring with immediate clinical-hours alerting
- Configure pulmonary hypertension echocardiography with immediate radiology-hours alerting
- Add ruxolitinib/baricitinib prescribing and dose escalation platforms with immediate clinical-hours alerting
- Configure weekly CBC (dose escalation safety) with immediate laboratory-hours alerting
- Add LFT and lipid monitoring with immediate laboratory-hours alerting
- Configure PCP prophylaxis prescribing and adherence with immediate clinical-hours alerting
- Add digital vasculopathy wound documentation with immediate clinical-hours alerting
- Configure iloprost and vascular intervention records with sustained-failure alerting
- Add interferonopathy registry and clinical trial access with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to JAK inhibitor dose escalation protocols, ISG score laboratory emergency procedures, and TMEM173 laboratory emergency procedures
Conclusion
SAVI technology platforms are embedded in clinical decisions where ISG score platform availability when a 4-month-old SAVI patient on baricitinib has a scheduled ISG score check that will determine whether the baricitinib dose has sufficiently suppressed the type I interferon signature — when the clinical immunology platform must return the ISG15, IFIT1, IFIT2, IFIT3, RSAD2, and SIGLEC1 transcript quantification that confirms interferon suppression before the next HRCT is performed — cannot be disrupted by ISG score platform failures that leave the pediatric rheumatologist without the biomarker data that should precede imaging and drive the dose titration decision; where HRCT platform availability when a 2-year-old SAVI patient on ruxolitinib is scheduled for a 6-month pulmonary surveillance CT — when the pulmonologist must confirm whether the ground-glass opacification percentage on the current scan is lower, equal, or higher than the 6-month-ago scan to determine whether ruxolitinib is arresting ILD progression or whether the dose must be escalated before irreversible fibrotic remodeling replaces reversible ground-glass inflammation — cannot be disrupted by HRCT scheduling platform failures that defer the critical imaging that determines whether JAK inhibitor escalation has already been delayed too long; and where TMEM173 genetic testing platform availability for a 3-week-old with neonatal-onset ILD on chest CT, digital telangiectases on both hands, markedly elevated ferritin, and an ISG score 18 times the upper limit of normal — when the interferonopathy specialist suspects SAVI and orders the TMEM173 gain-of-function panel to confirm the diagnosis and immediately initiate baricitinib while the panel is pending — cannot be disrupted by TMEM173 panel platform failures that extend the diagnostic uncertainty interval during which a neonate's ILD is progressing without type I interferon suppression. An ISG score platform unavailable when JAK inhibitor dose adequacy must be confirmed, an HRCT scheduling platform unavailable when ILD progression must be documented before irreversible fibrosis accrues, a TMEM173 diagnostic platform unavailable when a neonate's interferonopathy requires urgent genetic confirmation to initiate JAK inhibition — these are not IT incidents. They are clinical disruptions in the management of one of the most severe and rapidly fatal type I interferonopathies identified, where neonatal ILD progression, digital autoamputation, and constitutive interferon activation demand ISG score precision, HRCT surveillance continuity, and JAK inhibitor management reliability that can only be guaranteed by dedicated platform monitoring.
Uptime monitoring gives SAVI tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to type I interferonopathy centers of excellence, clinical immunology ISG score laboratories, pediatric pulmonology ILD programs, TMEM173 molecular genetic testing services, specialty pharmacies managing baricitinib and ruxolitinib, and compliance auditors that platform operational reliability matches the neonatal-onset urgency, type I interferon signature monitoring precision, ILD surveillance intensity, and JAK inhibitor safety management demands of modern SAVI care.
Start monitoring your SAVI care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #SAVI #STING #TMEM173 #interferonopathy #type1 #interferon #ISG #score #ILD #interstitial #lung #disease #HRCT #JAK #inhibitor #ruxolitinib #baricitinib #vasculopathy #digital #ischemia #neonatal #autoinflammatory #rare #disease #HIPAA #healthtech #digitalhealth #uptime #sre